

**AWMSG ADVICE SUPERSEDED BY
NICE GUIDANCE (TA387)
NICE GUIDANCE ISSUED APRIL 2016**

(Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology)

Final Appraisal Recommendation

Advice No: 1614 – June 2014

Abiraterone acetate (Zytiga[®]▼) 250 mg tablets

Submission by Janssen-Cilag Ltd

Recommendation of AWMSG

Abiraterone acetate (Zytiga[®]▼) with prednisone or prednisolone is not recommended for use within NHS Wales for the treatment of metastatic castration-resistant prostate cancer in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated.

The case for cost effectiveness has not been proven.

Additional notes:

- AWMSG acknowledged that the criteria for appraising life-extending, end-of-life medicines did not apply to abiraterone acetate (Zytiga[®]▼) for the indication under consideration. The median overall survival of patients in the control group of study COU-AA-302 was 30.1 months.
- Patients who are currently being treated with abiraterone acetate (Zytiga[®]▼) for the indication stated above should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 1794), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at www.evidence.nhs.uk.

For full details on our accreditation visit: www.nice.org.uk/accreditation.

This recommendation has been ratified by the Minister for Health and Social Services and will be considered for review in three years.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 1614:
Abiraterone acetate (Zytiga[®]▼) 250 mg tablets. June 2014.